Key Highlights

  • 10.28% is the indicated pre-market decline for Haoxi Health Technology Limited (NASDAQ:HAO) on November 17, 2026, with the price at USD 1.79 against a calculated prior close of USD 1.9951, a calculated move of USD 0.2051.
  • 1-for-128 is the reverse share split ratio approved on March 24, 2026, which took effect for Class A shares on May 21, 2026 and raised Par Value from USD 0.0025 to USD 0.32 per share.
  • 235,504,007 Class A shares were outstanding before that split and about 1,839,876 afterward, with Class B shares falling from 690,800 to about 5,397, according to the company release of May 19, 2026.
  • 67% is the fiscal 2026 Revenue growth reported in published coverage, to USD 54.8 million, while gross Margin compressed to 1.15% and the allowance for Credit losses reached about USD 6.07 million.

What Moved Haoxi Health Technology Limited (NASDAQ:HAO) in Pre-Market Trading on November 17, 2026 (-USD 0.2051, -10.28%)

The indicated pre-market price for Haoxi Health Technology Limited (NASDAQ:HAO) is USD 1.79 on November 17, 2026, a pre-market move of -10.28%. The calculated prior close is USD 1.9951 (USD 1.79 divided by 0.8972), and the calculated USD move is -USD 0.2051. A corroborated current market Capitalization was not found because the share count has changed since the May 2026 reverse split. Pre-market Volume was not found, and early sessions are typically thin.

The Rationale: No Single Catalyst Identified for Haoxi Health Technology Limited (NASDAQ:HAO)

No catalyst for the November 17, 2026 move was identified in published coverage. As general context, a recently reverse-split small-cap with a limited float can swing sharply on modest order flow, and pre-market illiquidity widens moves in either direction. In May 2026 the company announced a registered direct offering with stated gross proceeds of USD 6.5 million, with net proceeds earmarked for Working Capital and general corporate purposes. The company describes its growth as driven by rising newsfeed Advertising and rapid growth in the healthcare sector. The ticker remained HAO after the split.

Valuation, Liquidity and Risks for Haoxi Health Technology Limited (NASDAQ:HAO)

Published coverage of fiscal 2026 results cites revenue of USD 54.8 million, up 67%, but gross margin of 1.15% versus 2.83% in 2025 and 5.67% in 2024, which leaves little room for error. Operating cash used was USD 2.57 million versus USD 3.36 million, a USD 1.5 million intangible asset write-down was recorded, and USD 4.5 million was placed in a convertible bond. Concentration is high, with Ocean Engine at 99.4% of procurement and the chief executive holding 83.83% of voting power. Repeated reverse splits and offerings signal dilution risk for small-cap holders.

Where Things Stand

Haoxi Health Technology Limited (NASDAQ:HAO) is indicated down 10.28% in pre-market trading on November 17, 2026, at USD 1.79, a calculated drop of USD 0.2051 from a prior close of USD 1.9951. No specific catalyst was identified in published coverage. The company completed a 1-for-128 reverse split on May 21, 2026 and reports revenue of USD 54.8 million with a gross margin of 1.15%. Supplier concentration of 99.4%, an allowance for credit losses of about USD 6.07 million and dilution from financings remain central risks. This article is informational and is not Investment advice.